Concert Pharmaceuticals, Inc.

Symbol: CNCE




Market price today

  • -3.4866

    P/E Ratio

  • -0.0222

    PEG Ratio

  • 401.95M

    MRK Cap

  • 0.00%

    DIV Yield

Concert Pharmaceuticals, Inc. (CNCE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Roger D. Tung Ph.D.
Full-time employees:64
Address:65 Hayden Avenue

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

General Outlook

In simple terms, Concert Pharmaceuticals, Inc. has 48.023 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.379%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -2.535%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.500% return, is a testament to Concert Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Concert Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.679%. Furthermore, the proficiency of Concert Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.520% return on capital employed.

Stock Prices

Concert Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8.39, while its low point bottomed out at $8.37. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Concert Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing CNCE liquidity ratios reveals its financial health of the firm. The current ratio of 932.56% gauges short-term asset coverage for liabilities. The quick ratio (889.06%) assesses immediate liquidity, while the cash ratio (878.64%) indicates cash reserves.

Current Ratio932.56%
Quick Ratio889.06%
Cash Ratio878.64%

Profitability Ratios

CNCE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -245.72% underscores its earnings before tax deductions. The effective tax rate stands at -3.18%, revealing its tax efficiency. The net income per EBT, 103.18%, and the EBT per EBIT, 103.28%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -237.92%, we grasp its operational profitability.

Pretax Profit Margin-245.72%
Effective Tax Rate-3.18%
Net Income per EBT103.18%
EBT per EBIT103.28%
EBIT per Revenue-237.92%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 9.33, it details the span from stock purchase to revenue. The 9 days it takes to settle debts showcases its creditor relations. Meanwhile, a 9 cash conversion cycle and 14944.04% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding889
Receivables Turnover149.44
Fixed Asset Turnover2.36
Asset Turnover0.20

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.60, and free cash flow per share, -1.61, depict cash generation on a per-share basis. The cash per share value, 4.16, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.69, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.60
Free Cash Flow per Share-1.61
Cash per Share4.16
Operating Cash Flow Sales Ratio-1.69
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-3.66
Short Term Coverage Ratio-47.75
Capital Expenditure Coverage Ratio-216.29
Dividend Paid and Capex Coverage Ratio-216.29

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 9.11%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.13, we discern the balance between debt and equity financing. The long-term debt to capitalization, 11.03%, and total debt to capitalization, 11.84%, ratios shed light on its capital structure.

Debt Ratio9.11%
Debt Equity Ratio0.13
Long Term Debt to Capitalization11.03%
Total Debt to Capitalization11.84%
Cash Flow to Debt Ratio-3.66
Company Equity Multiplier1.47

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.95, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.40, reflects the portion of profit attributed to each share. The book value per share, 3.26, represents the net asset value distributed per share, while the tangible book value per share, 3.26, excludes intangible assets.

Revenue Per Share0.95
Net Income Per Share-2.40
Book Value Per Share3.26
Tangible Book Value Per Share3.26
Shareholders Equity Per Share3.26
Interest Debt Per Share0.44
Capex Per Share-0.01

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -18,195,250, captures the company's total value, considering both debt and equity. Income quality, 0.69, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.68, gauges operational efficiency, while the research and development to revenue, 268.75%, highlights investment in innovation.

Enterprise Value-18,195,250
Income Quality0.69
Sales General and Administrative to Revenue0.68
Research and Development to Revenue268.75%
Capex to Operating Cash Flow0.46%
Capex to Revenue-0.78%
Capex to Depreciation-17.24%
Stock-Based Compensation to Revenue38.59%
Graham Number13.27
Return on Tangible Assets-49.96%
Graham Net Net2.62
Working Capital134,209,000
Tangible Asset Value112,225,000
Net Current Asset Value97,238,000
Average Receivables1,697,500
Average Payables1,418,000
Average Inventory-26,383,000
Days Sales Outstanding2

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.57, and the price to book ratio, 2.57, reflect the market's valuation relative to the company's book value. The price to sales ratio, 12.34, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -7.25, and price to operating cash flows, -5.22, gauge market valuation against cash flow metrics.

Price Book Value Ratio2.57
Price to Book Ratio2.57
Price to Sales Ratio12.34
Price Cash Flow Ratio-5.22
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-7.19
Price Fair Value2.57
Price to Operating Cash Flow Ratio-5.22
Price to Free Cash Flows Ratio-7.25
Price to Tangible Book Ratio0.97
Enterprise Value to Sales-0.56
Enterprise Value Over EBITDA0.25
EV to Operating Cash Flow0.33
Earnings Yield-76.21%
Free Cash Flow Yield-51.13%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Concert Pharmaceuticals, Inc. (CNCE) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.487 in 2024.

What is the ticker symbol of Concert Pharmaceuticals, Inc. stock?

The ticker symbol of Concert Pharmaceuticals, Inc. stock is CNCE.

What is company IPO date?

IPO date of Concert Pharmaceuticals, Inc. is 2014-02-13.

What is company current share price?

Current share price is 8.370 USD.

What is stock market cap today?

The market cap of stock today is 401949162.000.

What is PEG ratio in 2024?

The current -0.022 is -0.022 in 2024.

What is the number of employees in 2024?

In 2024 the company has 64.